Global Longlife Hospital and Research Ltd (GLHRL) Fair Value & Analysis
Healthcare · IN · Market cap ₹114M
Fair value as of: Aug 13, 2026
From 1 valuation models · updated 6 days ago
Share price −9.5% over the past month.
A solid business, screening 81% undervalued on our models.
What matters now
- The price is below even our cautious bear case (₹12.75). The market is more pessimistic than our downside scenario.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- Solid quality (60/100) at a price below fair value, the discount is the argument here, not the business quality.
- A fairly wide model range (₹12.75 to ₹24.15) leaves room in how you read the outcome.
Price vs Fair Value (4 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
52‑month range ₹9.47 – ₹135.35 · fair‑value band ₹12.75 – ₹24.15 · the ₹10.68 price screens below the ₹19.32 fair value. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Global Longlife Hospital and Research Ltd (GLHRL) currently trades at ₹10.68, while our model-based Fair Value estimate is ₹19.32, implying the stock looks roughly 80.9% undervalued today. The Quality Score stands at 60/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low), always confirm before acting.
Trailing-twelve-month revenue stands at ₹52.0K. It earns a return on equity of -6.8%. Net debt stands at ₹124M. Fundamentals as of Aug 13, 2026
Our scenario range runs from ₹12.75 (bear case) to ₹24.15 (bull case); at ₹10.68, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 60% below its 52-week high and 10% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -31% fair-value upside, at 81%, GLHRL screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 1 models by family
Notify me when GLHRL reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 65 · Market factors (momentum, volatility) 22
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Global Longlife Hospital and Research Limited, a multispecialty hospital, provides medical and allied services in India.
Full company description
Global Longlife Hospital and Research Limited, a multispecialty hospital, provides medical and allied services in India. It offers medical services, such as oncology, ophthalmology, allergy and immunology, pain management, pulmonology, anaesthesiology, cardiology, dermatology, critical care, diabetes and endocrinology, GI medicine, gynecology, infectious disease, nephrology, and neurology; and surgical services, including CVTS, joint replacement orthopaedics, spine surgery, general surgery, onco surgery, GI surgery, neurosurgery, ENT, plastic surgery, trauma centre, urology, laparoscopic surgery, gynaecology, dental surgery, and vascular surgery. The company also provides radiology services consisting of mammography, CT scan, X-ray, ultrasound, endoscopy, and sonography; pathology services, including microbiology, biochemistry, clinical pathology, cyto pathology, haematology, and serology; and other services comprising dialysis, pharmacy, ambulance, dietary, and physiotherapy services. Global Longlife Hospital and Research Limited was Incorporated in 2012 and is based in Ahmedabad, India.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Global Longlife Hospital and Research Ltd reported revenue of ₹0 in FY2026 versus ₹328M in FY2022. Reported net income was −₹17.2M in FY2026.
Watch GLHRL: get an alert when its fair value changes →
Peer Group
Medical Care Facilities · 269 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Care Facilities median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc HCA | $414.59 | $547.67 | +32% |
| Fresenius SE FRE | €46.82 | €32.15 | -31% |
| Dr. Sulaiman Al Habib Medical Services Group 4013 | 235.00 SAR | 112.37 SAR | -52% |
| IHH Healthcare Berhad, an investment holding company, Q0F | 2.67 SGD | 1.44 SGD | -46% |
| Rede D'Or São Luiz S.A RDOR3 | R$33.09 | R$47.31 | +43% |
| Apollo Hospitals Enterprise Limited APOLLOHOSP | ₹8,818 | ₹2,955 | -66% |
| Aier Eye Hospital Group 300015 | ¥8.87 | ¥7.67 | -14% |
| Max Healthcare Institute Limited MAXHEALTH | ₹1,008 | ₹284.87 | -72% |
| Bangkok Dusit Medical Services Public Company BDMS | 19.40 THB | 18.57 THB | -4% |
| Fortis Healthcare Limited FORTIS | ₹906.15 | ₹300.29 | -67% |
Compare Global Longlife Hospital and Research Ltd with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Global Longlife Hospital and Research Ltd (GLHRL) overvalued or undervalued?
What is the fair value of GLHRL?
What is the quality score of GLHRL?
What is the revenue of Global Longlife Hospital and Research Ltd (GLHRL)?
What is the net profit margin of GLHRL?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Global Longlife Hospital and Research Ltd and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.